A Phase 3 interventional study of RNF and RNF in Multiple Sclerosis and Clinically Isolated Syndrome, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 57 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-08.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 3, and was the 16th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 8 · Phase 4 15
First in 1999; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 402 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 85 across the 34 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 34 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany: none open now, 1 under way, none of them phase 3. Of 70 finished, 42 (60%) have results posted.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 7th largest by enrollment of the 33 interventional ones that give a count, is one of 13 that started in 2008, is one of 11 in phase 3, and was the 12th registered.
Merck KGaA, Darmstadt, Germany’s Multiple Sclerosis studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 71 in Multiple Sclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a first demyelinating event at high risk of converting to MS, treated with fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of interferon [IFN]-beta-1a (RNF).
The objective of the study is to investigate whether RNF treatment initiated after the first clinical event versus delayed treatment results in the prolongation of time to Clinically Definite Multiple Sclerosis (CDMS) conversion up to Month 36 and up to Month 60 since randomization in Study 27025 (REFLEX). Furthermore, the study is intended to explore whether RNF treatment initiated after the first clinical event versus delayed treatment delays disability (including development of secondary progressive MS) and reduces disease activity (including the annual relapse rate [ARR]) in the long term (up to Month 36 and up to Month 60 since randomization in Study 27025 (REFLEX). The study will also assess the long-term safety profile of RNF (up to Month 36 and up to Month 60 since randomization in Study 27025 (REFLEX).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, subject must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: RNF
Drug: RNF · Drug: Placebo
Drug: RNF
Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
Also known as: Rebif®
Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
Also known as: Rebif®
Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
Also known as: Rebif®
Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score up to 36 Months
CDMS was defined by the occurrence of a second attack or relapse over 36 months in participants who presented with clinically isolated syndrome (CIS) accompanied by an abnormal magnetic resonance imaging (MRI) scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis \[MS\]) was calculated. Time to conversion to CDMS was represented by Kaplan-Meier estimates of the cumulative percentage (%) of participants with CDMS.
Time frame: Baseline (Day 1 of Study 27025) up to 36 Months
Time to Confirmed Expanded Disability Status Scale (EDSS) Progression up to 36 Months
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. Time to confirmed EDSS progression was represented by Kaplan-Meier estimates of the cumulative percentage (%) of participants with confirmed EDSS progression.
Time frame: Baseline (Day 1 of Study 27025) up to 36 Months
Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, New Gadolinium Enhanced (Gd+) Lesions and New Time Constant 1 (T1) Lesions Per Participant Per Scan at Month 36
Number of CUA lesions, new T2 lesions, new Gd+ lesions and new T1 lesions were measured by using MRI scans.
Time frame: Month 36
Change From Baseline in Time Constant 1 (T1) Hypointense Lesion Volume and Time Constant 2 (T2) Lesion Volume at Month 36
Change from baseline in lesion volume was measured by using MRI scans for T1 hypointense lesions and T2 lesions at Month 36
Time frame: Baseline (Day 1 of Study 27025), Month 36
Percent Change From Baseline in Brain Volume at Month 36
Percent change in brain volume was measured by using MRI scans.
Time frame: Baseline (Day 1 of Study 27025), Month 36
Percentage of Participants With Conversion to McDonald Multiple Sclerosis (MS) up to 36 Months
The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.
Time frame: Baseline (Day 1 of Study 27025) up to CDMS conversion and/or up to 36 Months
Change From Baseline in Paced Auditory Serial Addition Test 3 (PASAT-3) Score at Month 36
The Paced Auditory Serial Addition Test (PASAT) is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Score ranges from '0-60'. Higher scores reflect better neurological function and a positive change from baseline indicates improvement.
Time frame: Baseline (Day of Study 27025), Month 36
Percentage of Relapse-Free Participants at Month 36
A relapse was defined as the development of new or the exacerbation of existing neurological symptoms or signs, in the absence of fever, lasting for 24 hours and with a previous period for more than 30 days with a stable or an improving condition.
Time frame: Month 36
Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Month 36
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS score at Month 36 was calculated as EDSS score at Month 36 minus EDSS score at baseline.
Time frame: Baseline (Day of Study 27025), Month 36
Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Month 36
The MSFC is a multidimensional clinical outcome measure which consists of three sub-tests; Timed 25-Foot Walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test-3(PASAT-3). The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The 9-Hole Peg Test is a quantitative measure of upper extremity (arm and hand) function. The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Standardized results (Z-scores) of these sub-tests and the overall MSFC Z-score as an average of these three Z-scores was calculated. Higher Z-scores reflect better neurological function and a positive change from baseline indicates improvement. An increase in score indicates an improvement (range -3 to +3).
Time frame: Baseline (Day 1 of Study 27025), Month 36
Numbers of Participants With Binding Antibodies (BAb) and Neutralizing Antibody (NAb) at Month 36
BAbs are all antibodies which are capable of binding to the investigational drug molecule (RNF) irrespective of their binding site. NAbs are defined as a subgroup of BAbs which bind to the active sites of the RNF and therefore neutralize its potency. NAbs were detected using a viral cytopathic assay. BAbs were measured by using an ELISA (Enzyme-linked immunosorbent assay).
Time frame: Month 36
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation
An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.
Time frame: Month 24 up to Month 36 (DB treatment period for study 28981 (REFLEXION)
Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score up to Month 60
CDMS was defined by the occurrence of a second attack or relapse over 60 months in participants who presented with clinically isolated syndrome (CIS) accompanied by an abnormal magnetic resonance imaging (MRI) scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis \[MS\]) was calculated. Time to conversion to CDMS was represented by Kaplan-Meier estimates of the cumulative percentage (%) of participants with CDMS.
Time frame: Baseline (Day 1 of Study 27025) up to 60 Months
Time to Confirmed Expanded Disability Status Scale (EDSS) Progression up to 60 Months
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. Time to confirmed EDSS progression was represented by Kaplan-Meier estimates of the cumulative percentage (%) of participants with confirmed EDSS progression.
Time frame: Baseline (Day 1 of Study 27025) up to 60 Months
Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, New Gadolinium Enhanced (Gd+) Lesions and New T1 Lesions Per Participant Per Scan at Month 60
Number of CUA lesions, new T2 lesions, new Gd+ Lesions and new T1 lesions were measured by using MRI scans.
Time frame: Month 60
Change From Baseline in Time Constant 1 (T1) Hypointense Volume, and Time Constant 2 (T2) Lesion Volume at Month 60
Change from baseline in lesion volume was measured by using MRI scans for T1 hypointense lesions and T2 lesions.
Time frame: Baseline (Day 1 of Study 27025), Month 60
Percent Change From Baseline in Brain Volume at Month 60
Percent Change in brain volume was measured by using MRI scans.
Time frame: Baseline (Day 1 of Study 27025), Month 60
Percentage of Participants With Conversion to McDonald Multiple Sclerosis (MS) at Month 60
The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.
Time frame: Month 60
Change From Baseline in Paced Auditory Serial Addition Test 3 (PASAT-3) Score at Month 60
The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Score ranges from '0-60'. Higher scores reflect better neurological function and a positive change from baseline indicates improvement.
Time frame: Baseline (Day 1 of Study 27025), Month 60
Percentage of Relapse-Free Participants at Month 60
A relapse was defined as the development of new or the exacerbation of existing neurological symptoms or signs, in the absence of fever, lasting for 24 hours and with a previous period for more than 30 days with a stable or an improving condition.
Time frame: Month 60
Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Month 60
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS score at Month 60 was calculated as EDSS score at Month 60 minus EDSS score at baseline.
Time frame: Baseline (Day 1 of Study 27025), Month 60
Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Month 60
The MSFC is a multidimensional clinical outcome measure which consists of three sub-tests; Timed 25-Foot Walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test-3(PASAT-3). The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The 9-Hole Peg Test is a quantitative measure of upper extremity (arm and hand) function. The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Standardized results (Z-scores) of these sub-tests and the overall MSFC Z-score as an average of these three Z-scores was calculated. Higher Z-scores reflect better neurological function and a positive change from baseline indicates improvement. An increase in score indicates an improvement (range -3 to +3).
Time frame: Baseline (Day 1 of Study 27025), Month 60
Numbers of Participants With Binding Antibodies (BAb) and Neutralizing Antibody (NAb) at Month 60
BAbs are all antibodies which are capable of binding to the RNF irrespective of their binding site. NAbs are defined as a subgroup of BAbs which bind to the active sites of the RNF and therefore neutralize its potency. NAbs were detected using a viral cytopathic assay. BAbs were measured by using an ELISA.
Time frame: Month 60
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation
An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.
Time frame: Month 24 up to Month 60
Participants who were randomized in Study 27025 (NCT00404352) were eligible to enroll into extension Study 28981 (NCT00813709) whether or not they completed main study on Investigational Medicinal Product (IMP), or no treatment or received other disease-modifying drugs (DMDs) during course of main study. No re-randomization was done for this study.
| Milestone | Placebo/RNF 44 Mcg Thrice Weekly (DB Population) | RNF 44 Mcg Once Weekly (DB Population) | RNF 44 Mcg Thrice Weekly (DB Population) | Placebo/RNF 44 Mcg Thrice Weekly/OL RNF 44 Mcg Thrice Weekly | RNF 44 Mcg Once Weekly /OL RNF 44 Mcg Thrice Weekly | RNF 44 Mcg Thrice Weekly/OL RNF 44 Mcg Thrice Weekly |
|---|---|---|---|---|---|---|
| Started | 84 | 117 | 99 | 0 | 0 | 0 |
| Treated | 83 | 114 | 98 | 0 | 0 | 0 |
| Completed | 53 | 76 | 68 | 0 | 0 | 0 |
| Not completed | 31 | 41 | 31 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 1 | 4 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Switched to open label phase | 9 | 26 | 18 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 1 | 3 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 14 | 9 | 6 | 0 | 0 | 0 |
| Milestone | Placebo/RNF 44 Mcg Thrice Weekly (DB Population) | RNF 44 Mcg Once Weekly (DB Population) | RNF 44 Mcg Thrice Weekly (DB Population) | Placebo/RNF 44 Mcg Thrice Weekly/OL RNF 44 Mcg Thrice Weekly | RNF 44 Mcg Once Weekly /OL RNF 44 Mcg Thrice Weekly | RNF 44 Mcg Thrice Weekly/OL RNF 44 Mcg Thrice Weekly |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 58 | 51 | 46 |
| Treated | 0 | 0 | 0 | 57 | 51 | 45 |
| Completed | 0 | 0 | 0 | 38 | 41 | 35 |
| Not completed | 0 | 0 | 0 | 20 | 10 | 11 |
| Withdrew: Adverse event | 0 | 0 | 0 | 5 | 4 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 3 | 1 | 1 |
| Withdrew: Randomized but not treated | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 11 | 5 | 6 |
CDMS was defined by the occurrence of a second attack or relapse over 36 months in participants who presented with clinically isolated syndrome (CIS) accompanied by an abnormal magnetic resonance imaging (MRI) scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis \[MS\]) was calculated. Time to conversion to CDMS was represented by Kaplan-Meier estimates of the cumulative percentage (%) of participants with CDMS.
| Cumulative % of participants with CDMS | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score up to 36 Months | 41.3 (33.5 to 49.1) | 27.6 (20.6 to 34.6) | 27.1 (19.9 to 34.3) |
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. Time to confirmed EDSS progression was represented by Kaplan-Meier estimates of the cumulative percentage (%) of participants with confirmed EDSS progression.
| % of participants with EDSS progression | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Time to Confirmed Expanded Disability Status Scale (EDSS) Progression up to 36 Months | 7.5 | 11.8 | 13.2 |
Number of CUA lesions, new T2 lesions, new Gd+ lesions and new T1 lesions were measured by using MRI scans.
| lesions | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| CUA Lesions | 1.02 ± 1.85 | 1.83 ± 3.317 | 1.63 ± 5.947 |
| New T2 Lesions | 0.83 ± 1.545 | 1.39 ± 2.573 | 1.19 ± 4.217 |
| New Gd+ Lesions | 0.17 ± 0.506 | 0.40 ± 1.354 | 0.41 ± 1.754 |
| New T1 Lesions | 0.69 ± 1.721 | 1.09 ± 2.482 | 0.91 ± 4.143 |
Change from baseline in lesion volume was measured by using MRI scans for T1 hypointense lesions and T2 lesions at Month 36
| cubic millimeter (mm^3) | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| T1 lesion volume at Baseline (n=171,175,171) | 670.3 ± 1054.1 | 774.8 ± 1288.0 | 675.0 ± 1049.9 |
| T1 lesion volume Change: Month 36(n=124,133,114) | 303.2 ± 1034.6 | 272.0 ± 921.4 | 133.3 ± 763.5 |
| T2 lesion volume at Baseline (n=171,175,171) | 3334.9 ± 3990.4 | 3853.1 ± 4716.7 | 3110.5 ± 3410.7 |
| T2 lesion volume Change: Month 36(n=124,133,114) | -3.8 ± 2101.8 | -56.9 ± 2436.3 | -398.1 ± 1415.4 |
Percent change in brain volume was measured by using MRI scans.
| percent change | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Percent Change From Baseline in Brain Volume at Month 36 | -1.02 ± 1.248 | -0.86 ± 1.073 | -1.14 ± 1.321 |
The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.
| percentage of participants | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Percentage of Participants With Conversion to McDonald Multiple Sclerosis (MS) up to 36 Months | 84.2 | 76.0 | 66.7 |
The Paced Auditory Serial Addition Test (PASAT) is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Score ranges from '0-60'. Higher scores reflect better neurological function and a positive change from baseline indicates improvement.
| units on a scale | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Baseline (n=171,175,171) | 0.0358 ± 0.8787 | -0.0909 ± 1.1223 | 0.0031 ± 1.1387 |
| Change at Month 36 (n=123,135,118) | 0.3483 ± 0.6949 | 0.5044 ± 0.7588 | 0.4515 ± 0.9164 |
A relapse was defined as the development of new or the exacerbation of existing neurological symptoms or signs, in the absence of fever, lasting for 24 hours and with a previous period for more than 30 days with a stable or an improving condition.
| Percentage of participants | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Percentage of Relapse-Free Participants at Month 36 | 42.7 | 58.3 | 51.5 |
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS score at Month 36 was calculated as EDSS score at Month 36 minus EDSS score at baseline.
| units on a scale | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Baseline (n=171,175,171) | 1.53 ± 0.77 | 1.50 ± 0.72 | 1.51 ± 0.83 |
| Change at Month 36 (n=120,136,116) | -0.21 ± 0.93 | -0.11 ± 0.96 | -0.09 ± 0.90 |
The MSFC is a multidimensional clinical outcome measure which consists of three sub-tests; Timed 25-Foot Walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test-3(PASAT-3). The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The 9-Hole Peg Test is a quantitative measure of upper extremity (arm and hand) function. The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Standardized results (Z-scores) of these sub-tests and the overall MSFC Z-score as an average of these three Z-scores was calculated. Higher Z-scores reflect better neurological function and a positive change from baseline indicates improvement. An increase in score indicates an improvement (range -3 to +3).
| Z-score | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| MFSC score at Baseline (n=171,175,171) | 0.0352 ± 0.5844 | 0.0071 ± 0.6653 | -0.0575 ± 0.6226 |
| Change at Month 36 (n=123,135,118) | 0.1993 ± 0.4863 | 0.2529 ± 0.5794 | 0.3074 ± 0.6071 |
BAbs are all antibodies which are capable of binding to the investigational drug molecule (RNF) irrespective of their binding site. NAbs are defined as a subgroup of BAbs which bind to the active sites of the RNF and therefore neutralize its potency. NAbs were detected using a viral cytopathic assay. BAbs were measured by using an ELISA (Enzyme-linked immunosorbent assay).
| participants | Placebo/RNF 44 Mcg Thrice Weekly (Integrated DB Population) | RNF 44 Mcg Once Weekly (Integrated DB Population) | RNF 44 Mcg Thrice Weekly (Integrated DB Population) |
|---|---|---|---|
| BAb- | 77 | 97 | 88 |
| BAb+ | 41 | 34 | 30 |
| NAb- | 100 | 109 | 99 |
| NAb+ | 18 | 22 | 19 |
An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.
| participants | Placebo/RNF 44 Mcg Thrice Weekly (DB Population) | RNF 44 Mcg Once Weekly (DB Population) | RNF 44 Mcg Thrice Weekly (DB Population) |
|---|---|---|---|
| AEs | 79 | 67 | 45 |
| SAEs | 3 | 2 | 4 |
| AEs leading to discontinuation | 2 | 0 | 2 |
CDMS was defined by the occurrence of a second attack or relapse over 60 months in participants who presented with clinically isolated syndrome (CIS) accompanied by an abnormal magnetic resonance imaging (MRI) scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis \[MS\]) was calculated. Time to conversion to CDMS was represented by Kaplan-Meier estimates of the cumulative percentage (%) of participants with CDMS.
| Cumulative % of participants with CDMS | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score up to Month 60 | 44.6 (36.6 to 52.6) | 40.7 (32.8 to 48.6) | 39.2 (30.8 to 47.6) |
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. Time to confirmed EDSS progression was represented by Kaplan-Meier estimates of the cumulative percentage (%) of participants with confirmed EDSS progression.
| % of participants with EDSS progression | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Time to Confirmed Expanded Disability Status Scale (EDSS) Progression up to 60 Months | 11.0 | 18.7 | 18.4 |
Number of CUA lesions, new T2 lesions, new Gd+ Lesions and new T1 lesions were measured by using MRI scans.
| lesions | Placebo/RNF 44 Mcg Thrice Weekly (ITT Population) | RNF 44 Mcg Once Weekly (ITT Population) | RNF 44 Mcg Thrice Weekly (ITT Population) |
|---|---|---|---|
| CUA Lesions (n=102, 121, 110) | 1.46 ± 3.394 | 1.60 ± 3.542 | 1.94 ± 4.803 |
| New T2 Lesions (n=102, 121, 110) | 1.17 ± 2.576 | 1.17 ± 2.628 | 1.35 ± 3.284 |
| New Gd+ Lesions (n=102, 121, 110) | 0.24 ± 0.823 | 0.36 ± 1.225 | 0.48 ± 1.618 |
| New T1 Lesions (n=102, 120, 110) | 0.57 ± 1.656 | 0.69 ± 1.659 | 0.71 ± 1.917 |
Change from baseline in lesion volume was measured by using MRI scans for T1 hypointense lesions and T2 lesions.
| mm^3 | Placebo/RNF 44 Mcg Thrice Weekly (ITT Population) | RNF 44 Mcg Once Weekly (ITT Population) | RNF 44 Mcg Thrice Weekly (ITT Population) |
|---|---|---|---|
| T1 lesion volume at Baseline (n=171,175,171) | 670.3 ± 1054.1 | 774.8 ± 1288.0 | 675.0 ± 1049.9 |
| Change at Month 60 (n=102,120,110) | 415.0 ± 1080.3 | 412.3 ± 1020.8 | 261.8 ± 1006.1 |
| T2 lesion volume at Baseline (n=171,175,171) | 3334.9 ± 3990.4 | 3853.1 ± 4716.7 | 3110.5 ± 3410.7 |
| Change at Month 60 (n=102,121,110) | 119.4 ± 2225.2 | 25.0 ± 2827.1 | -188.5 ± 2576.1 |
Percent Change in brain volume was measured by using MRI scans.
| percent change | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Percent Change From Baseline in Brain Volume at Month 60 | -1.82 ± 1.494 | -1.54 ± 1.378 | -2.03 ± 1.644 |
The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.
| percentage of participants | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Percentage of Participants With Conversion to McDonald Multiple Sclerosis (MS) at Month 60 | 84.2 | 82.9 | 72.5 |
The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Score ranges from '0-60'. Higher scores reflect better neurological function and a positive change from baseline indicates improvement.
| units on a scale | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Baseline (n=171, 175, 171) | 0.0358 ± 0.8787 | -0.0909 ± 1.1223 | 0.0031 ± 1.1387 |
| Change at Month 60 (n=112, 132, 118) | 0.4109 ± 0.6844 | 0.4785 ± 0.9886 | 0.4608 ± 0.8630 |
A relapse was defined as the development of new or the exacerbation of existing neurological symptoms or signs, in the absence of fever, lasting for 24 hours and with a previous period for more than 30 days with a stable or an improving condition.
| percentage of participants | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Percentage of Relapse-Free Participants at Month 60 | 34.5 | 45.1 | 40.9 |
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS score at Month 60 was calculated as EDSS score at Month 60 minus EDSS score at baseline.
| units on a scale | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| Baseline (n=171,175,171) | 1.53 ± 0.77 | 1.50 ± 0.72 | 1.51 ± 0.83 |
| Change at Month 60 (n=111,133,117) | -0.11 ± 0.94 | -0.01 ± 1.01 | 0.04 ± 1.02 |
The MSFC is a multidimensional clinical outcome measure which consists of three sub-tests; Timed 25-Foot Walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test-3(PASAT-3). The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The 9-Hole Peg Test is a quantitative measure of upper extremity (arm and hand) function. The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Standardized results (Z-scores) of these sub-tests and the overall MSFC Z-score as an average of these three Z-scores was calculated. Higher Z-scores reflect better neurological function and a positive change from baseline indicates improvement. An increase in score indicates an improvement (range -3 to +3).
| Z-score | Placebo/RNF 44 Mcg Thrice Weekly (Integrated ITT Population) | RNF 44 Mcg Once Weekly (Integrated ITT Population) | RNF 44 Mcg Thrice Weekly (Integrated ITT Population) |
|---|---|---|---|
| MFSC score at Baseline (n=171,175,171) | 0.0352 ± 0.5844 | 0.0071 ± 0.6653 | -0.0575 ± 0.6226 |
| Change at Month 60 (n=112,132,132) | 0.2290 ± 0.4824 | 0.2213 ± 0.5602 | 0.2192 ± 0.6229 |
BAbs are all antibodies which are capable of binding to the RNF irrespective of their binding site. NAbs are defined as a subgroup of BAbs which bind to the active sites of the RNF and therefore neutralize its potency. NAbs were detected using a viral cytopathic assay. BAbs were measured by using an ELISA.
| participants | Placebo/RNF 44 Mcg Thrice Weekly (Integrated DB Population) | RNF 44 Mcg Once Weekly (Integrated DB Population) | RNF 44 Mcg Thrice Weekly (Integrated DB Population) |
|---|---|---|---|
| BAb- | 89 | 99 | 100 |
| BAb+ | 25 | 30 | 15 |
| BAb (Missing) | 1 | 1 | 0 |
| NAb- | 97 | 110 | 102 |
| NAb+ | 18 | 20 | 13 |
An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.
| participants | Placebo/RNF 44 Mcg Thrice Weekly (DB Population) | RNF 44 Mcg Once Weekly (DB Population) | RNF 44 Mcg Thrice Weekly (DB Population) |
|---|---|---|---|
| AEs | 70 | 96 | 84 |
| SAEs | 7 | 7 | 9 |
| AEs leading to discontinuation | 3 | 0 | 2 |
Collected over Month 24 to 60 for both DB safety population and OL safety population. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/RNF 44 Mcg Thrice Weekly (DB Population) | — | 7/84 (8.3%) | 69/84 (82.1%) |
| RNF 44 Mcg Once Weekly (DB Population) | — | 7/117 (6%) | 97/117 (82.9%) |
| RNF 44 Mcg Thrice Weekly (DB Population) | — | 9/99 (9.1%) | 84/99 (84.8%) |
| Placebo/RNF 44 Mcg Thrice Weekly/OL RNF 44 Mcg Thrice Weekly | — | 2/58 (3.4%) | 46/58 (79.3%) |
| RNF 44 Mcg Once Weekly /OL RNF 44 Mcg Thrice Weekly | — | 3/51 (5.9%) | 37/51 (72.5%) |
| RNF 44 Mcg Thrice Weekly/OL RNF 44 Mcg Thrice Weekly | — | 4/46 (8.7%) | 36/46 (78.3%) |
| Event | Placebo/RNF 44 Mcg Thrice Weekly (DB Population) | RNF 44 Mcg Once Weekly (DB Population) | RNF 44 Mcg Thrice Weekly (DB Population) | Placebo/RNF 44 Mcg Thrice Weekly/OL RNF 44 Mcg Thrice Weekly | RNF 44 Mcg Once Weekly /OL RNF 44 Mcg Thrice Weekly | RNF 44 Mcg Thrice Weekly/OL RNF 44 Mcg Thrice Weekly |
|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/84 | 1/117 | 0/99 | 0/58 | 0/51 | 1/46 |
| Benign neoplasm of thyroid glandNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/84 | 0/117 | 0/99 | 0/58 | 0/51 | 1/46 |
| Lumbar radiculopathyNervous system disorders | 0/84 | 0/117 | 0/99 | 0/58 | 0/51 | 1/46 |
| Abortion missedPregnancy, puerperium and perinatal conditions | 0/84 | 1/117 | 0/99 | 0/58 | 0/51 | 1/46 |
| Eye haemorrhageEye disorders | 0/84 | 0/117 | 1/99 | 0/58 | 1/51 | 0/46 |
| Abdominal painGastrointestinal disorders | 0/84 | 0/117 | 0/99 | 0/58 | 1/51 | 0/46 |
| HypertensionVascular disorders | 0/84 | 0/117 | 0/99 | 0/58 | 1/51 | 0/46 |
| Abdominal pain upperGastrointestinal disorders | 0/84 | 0/117 | 0/99 | 1/58 | 0/51 | 0/46 |
| Acute coronary syndromeCardiac disorders | 0/84 | 0/117 | 0/99 | 1/58 | 0/51 | 0/46 |
| Peritonsillar abscessInfections and infestations | 1/84 | 0/117 | 0/99 | 0/58 | 0/51 | 0/46 |
| Event | Placebo/RNF 44 Mcg Thrice Weekly (DB Population) | RNF 44 Mcg Once Weekly (DB Population) | RNF 44 Mcg Thrice Weekly (DB Population) | Placebo/RNF 44 Mcg Thrice Weekly/OL RNF 44 Mcg Thrice Weekly | RNF 44 Mcg Once Weekly /OL RNF 44 Mcg Thrice Weekly | RNF 44 Mcg Thrice Weekly/OL RNF 44 Mcg Thrice Weekly |
|---|---|---|---|---|---|---|
| Influenza like illnessGeneral disorders | 45/84 | 39/117 | 17/99 | 11/58 | 12/51 | 10/46 |
| Injection site erythemaGeneral disorders | 17/84 | 6/117 | 8/99 | 4/58 | 8/51 | 2/46 |
| HeadacheNervous system disorders | 11/84 | 19/117 | 16/99 | 4/58 | 6/51 | 9/46 |
| OverdoseInjury, poisoning and procedural complications | 0/84 | 0/117 | 0/99 | 2/58 | 8/51 | 1/46 |
| NasopharyngitisInfections and infestations | 12/84 | 14/117 | 9/99 | 6/58 | 7/51 | 4/46 |
| Upper respiratory tract infectionInfections and infestations | 10/84 | 11/117 | 10/99 | 6/58 | 5/51 | 5/46 |
| Back painMusculoskeletal and connective tissue disorders | 5/84 | 7/117 | 6/99 | 5/58 | 2/51 | 5/46 |
| LeukopeniaBlood and lymphatic system disorders | 9/84 | 2/117 | 2/99 | 0/58 | 4/51 | 1/46 |
| NeutropeniaBlood and lymphatic system disorders | 8/84 | 3/117 | 5/99 | 0/58 | 4/51 | 1/46 |
| PharyngitisInfections and infestations | 0/84 | 0/117 | 0/99 | 2/58 | 0/51 | 4/46 |
Baseline data was presented for ITT population (402 participants) which included participants who had completed the REFLEX Study 27025 (NCT00404352) and were enrolled in this extension Study 28981 (REFLEXION).
| Age, Continuous(years) | Placebo/RNF 44 Mcg Thrice Weekly (ITT Population) | RNF 44 Mcg Once Weekly (ITT Population) | RNF 44 Mcg Thrice Weekly (ITT Population) | Total |
|---|---|---|---|---|
| Mean | 31.0 ± 8.2 | 31.4 ± 8.2 | 31.8 ± 8.6 | 31.4 ± 8.3 |
| Age, Customized(participants) | Placebo/RNF 44 Mcg Thrice Weekly (ITT Population) | RNF 44 Mcg Once Weekly (ITT Population) | RNF 44 Mcg Thrice Weekly (ITT Population) | Total |
|---|---|---|---|---|
| Less than 30 years | 67 | 66 | 55 | 188 |
| Greater than or equal to 30 years | 66 | 76 | 72 | 214 |
| Sex: Female, Male(Participants) | Placebo/RNF 44 Mcg Thrice Weekly (ITT Population) | RNF 44 Mcg Once Weekly (ITT Population) | RNF 44 Mcg Thrice Weekly (ITT Population) | Total |
|---|---|---|---|---|
| Female | 82 | 88 | 78 | 248 |
| Male | 51 | 54 | 49 | 154 |
| Race/Ethnicity, Customized(participants) | Placebo/RNF 44 Mcg Thrice Weekly (ITT Population) | RNF 44 Mcg Once Weekly (ITT Population) | RNF 44 Mcg Thrice Weekly (ITT Population) | Total |
|---|---|---|---|---|
| Black | 0 | 1 | 0 | 1 |
| White | 133 | 141 | 127 | 401 |
The record gives a start of Dec 2008, a primary completion of Aug 2011 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Merck KGaA, Darmstadt, Germany →